C9C70D33-C09B-4F7E-8F12-FDE51817038A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.006570302233904
- age_years
- 44
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.418
- INTERFERON_ALPHA_RESPONSE+0.367
- MYC_TARGETS_V2+0.365
- OXIDATIVE_PHOSPHORYLATION+0.354
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.352
- INTERFERON_GAMMA_RESPONSE+0.316
- MYC_TARGETS_V1+0.284
- ALLOGRAFT_REJECTION+0.278
- NOTCH_SIGNALING+0.266
- ADIPOGENESIS+0.253
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.374
- UV_RESPONSE_DN-0.351
- MITOTIC_SPINDLE-0.271
- SPERMATOGENESIS-0.214
- G2M_CHECKPOINT-0.208
- ESTROGEN_RESPONSE_EARLY-0.194
- KRAS_SIGNALING_DN-0.190
- PANCREAS_BETA_CELLS-0.186
- ANDROGEN_RESPONSE-0.138
- PROTEIN_SECRETION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 46C5EF69-5EAF-4FBA-BE47-28A8E7F3D9A2 | — | — | 0.899 |
| 2 | 77907EB2-E529-4633-A580-C6DD7993A704 | — | — | 0.846 |
| 3 | 31550B35-DA39-4294-8368-811A412B2E3A | — | — | 0.814 |
| 4 | cddceb59-733b-48d1-9b75-46c9949f7794 | — | — | 0.811 |
| 5 | MNG520 | — | — | 0.803 |
| 6 | E775874C-4CE0-4D23-8CF0-7A3D72A84DD9 | — | — | 0.797 |
| 7 | a8cd01e2-f7f4-487c-8cde-4fcf21bfe0e7 | — | — | 0.788 |
| 8 | TCGA-BA-A6DD-01A-12R-A31N-07 | — | — | 0.787 |
| 9 | TCGA-UF-A7JT-01A-11R-A34R-07 | — | — | 0.782 |
| 10 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.418 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.367 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.365 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.354 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.352 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.316 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.284 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.278 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.266 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.253 | Inavolisib | — uncovered |
| COAGULATION | 0.252 | Binimetinib | — uncovered |
| APOPTOSIS | 0.223 | Idelalisib | — uncovered |
| COMPLEMENT | 0.205 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.202 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.126 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.126 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.124 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.121 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.119 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.115 | Idelalisib | — uncovered |